Table of Content

Table of Contents

Global NASH Drug Pipeline Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global NASH Drug Pipeline Market by Value
2.2.1 Global NASH Drug Pipeline Revenue by Type
2.2.2 Global NASH Drug Pipeline Market by Value (%)
2.3 Global NASH Drug Pipeline Market by Production
2.3.1 Global NASH Drug Pipeline Production by Type
2.3.2 Global NASH Drug Pipeline Market by Production (%)

3. The Major Driver of NASH Drug Pipeline Industry
3.1 Historical & Forecast Global NASH Drug Pipeline Demand
3.2 Largest Application for NASH Drug Pipeline (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional NASH Drug Pipeline Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of NASH Drug Pipeline Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US NASH Drug Pipeline Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe NASH Drug Pipeline Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China NASH Drug Pipeline Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan NASH Drug Pipeline Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India NASH Drug Pipeline Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea NASH Drug Pipeline Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia NASH Drug Pipeline Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global NASH Drug Pipeline Average Price Trend
12.1 Market Price for Each Type of NASH Drug Pipeline in US (2018-2022)
12.2 Market Price for Each Type of NASH Drug Pipeline in Europe (2018-2022)
12.3 Market Price for Each Type of NASH Drug Pipeline in China (2018-2022)
12.4 Market Price for Each Type of NASH Drug Pipeline in Japan (2018-2022)
12.5 Market Price for Each Type of NASH Drug Pipeline in India (2018-2022)
12.6 Market Price for Each Type of NASH Drug Pipeline in Korea (2018-2022)
12.7 Market Price for Each Type of NASH Drug Pipeline in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 NASH Drug Pipeline Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of NASH Drug Pipeline

14. NASH Drug Pipeline Competitive Landscape
14.1 Intercept
14.1.1 Intercept Company Profiles
14.1.2 Intercept Product Introduction
14.1.3 Intercept NASH Drug Pipeline Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Genfit
14.2.1 Genfit Company Profiles
14.2.2 Genfit Product Introduction
14.2.3 Genfit NASH Drug Pipeline Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Allergan
14.3.1 Allergan Company Profiles
14.3.2 Allergan Product Introduction
14.3.3 Allergan NASH Drug Pipeline Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Madrigal
14.4.1 Madrigal Company Profiles
14.4.2 Madrigal Product Introduction
14.4.3 Madrigal NASH Drug Pipeline Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Immuron
14.5.1 Immuron Company Profiles
14.5.2 Immuron Product Introduction
14.5.3 Immuron NASH Drug Pipeline Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Galectin
14.6.1 Galectin Company Profiles
14.6.2 Galectin Product Introduction
14.6.3 Galectin NASH Drug Pipeline Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Gilead
14.7.1 Gilead Company Profiles
14.7.2 Gilead Product Introduction
14.7.3 Gilead NASH Drug Pipeline Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 89bio Inc
14.8.1 89bio Inc Company Profiles
14.8.2 89bio Inc Product Introduction
14.8.3 89bio Inc NASH Drug Pipeline Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 ABIONYX Pharma SA
14.9.1 ABIONYX Pharma SA Company Profiles
14.9.2 ABIONYX Pharma SA Product Introduction
14.9.3 ABIONYX Pharma SA NASH Drug Pipeline Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Abivax SA
14.10.1 Abivax SA Company Profiles
14.10.2 Abivax SA Product Introduction
14.10.3 Abivax SA NASH Drug Pipeline Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Abliva AB
14.12 Acquist Therapeutics
14.13 AdAlta Ltd
14.14 Afimmune Biopharma Ltd
14.15 Zhejiang Doer Biologics Corp
14.16 Dicerna Pharmaceuticals Inc
14.17 ChemomAb Ltd
14.18 DURECT Corp
14.19 Eli Lilly and Co
14.20 Enanta Pharmaceuticals Inc
14.21 EncuraGen Inc
14.22 Engitix Ltd
14.23 Heprotech Inc
14.24 Hinova Pharmaceuticals Inc
14.25 HK inno.N Corp
14.26 HotSpot Therapeutics Inc
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of NASH Drug Pipeline Industry (Volume)
Figure 2. NASH Drug Pipeline Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by NASH Drug Pipeline Revenue in 2022
Figure 5. US NASH Drug Pipeline Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe NASH Drug Pipeline Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China NASH Drug Pipeline Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan NASH Drug Pipeline Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India NASH Drug Pipeline Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea NASH Drug Pipeline Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia NASH Drug Pipeline Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. NASH Drug Pipeline Revenue, by Type (Million USD) (2018-2028)
Table 4. NASH Drug Pipeline Production, by Type (K Unit) (2018-2028)
Table 5. NASH Drug Pipeline Demand (K Unit) by Application (2018-2028)
Table 6. NASH Drug Pipeline Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top NASH Drug Pipeline Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia NASH Drug Pipeline Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of NASH Drug Pipeline in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Intercept Profiles
Table 61. Intercept NASH Drug Pipeline Product Introduction
Table 62. Intercept NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Intercept Strategic initiatives
Table 64. Genfit Profiles
Table 65. Genfit NASH Drug Pipeline Product Introduction
Table 66. Genfit NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Genfit Strategic initiatives
Table 68. Allergan Profiles
Table 69. Allergan NASH Drug Pipeline Product Introduction
Table 70. Allergan NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Allergan Strategic initiatives
Table 72. Madrigal Profiles
Table 73. Madrigal NASH Drug Pipeline Product Introduction
Table 74. Madrigal NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Madrigal Strategic initiatives
Table 76. Immuron Profiles
Table 77. Immuron NASH Drug Pipeline Product Introduction
Table 78. Immuron NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Immuron Strategic initiatives
Table 80. Galectin Profiles
Table 81. Galectin NASH Drug Pipeline Product Introduction
Table 82. Galectin NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Galectin Strategic initiatives
Table 84. Gilead Profiles
Table 85. Gilead NASH Drug Pipeline Product Introduction
Table 86. Gilead NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. Gilead Strategic initiatives
Table 88. 89bio Inc Profiles
Table 89. 89bio Inc NASH Drug Pipeline Product Introduction
Table 90. 89bio Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. 89bio Inc Strategic initiatives
Table 92. ABIONYX Pharma SA Profiles
Table 93. ABIONYX Pharma SA NASH Drug Pipeline Product Introduction
Table 94. ABIONYX Pharma SA NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. ABIONYX Pharma SA Strategic initiatives
Table 97. Abivax SA Profiles
Table 98. Abivax SA NASH Drug Pipeline Product Introduction
Table 99. Abivax SA NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Abivax SA Strategic initiatives
Table 101. Abliva AB Profiles
Table 102. Abliva AB NASH Drug Pipeline Product Introduction
Table 103. Abliva AB NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Abliva AB Strategic initiatives
Table 105. Acquist Therapeutics Profiles
Table 106. Acquist Therapeutics NASH Drug Pipeline Product Introduction
Table 107. Acquist Therapeutics NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 108. Acquist Therapeutics Strategic initiatives
Table 109. AdAlta Ltd Profiles
Table 110. AdAlta Ltd NASH Drug Pipeline Product Introduction
Table 111. AdAlta Ltd NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 112. AdAlta Ltd Strategic initiatives
Table 113. Afimmune Biopharma Ltd Profiles
Table 114. Afimmune Biopharma Ltd NASH Drug Pipeline Product Introduction
Table 115. Afimmune Biopharma Ltd NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 116. Afimmune Biopharma Ltd Strategic initiatives
Table 117. Zhejiang Doer Biologics Corp Profiles
Table 118. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Introduction
Table 119. Zhejiang Doer Biologics Corp NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 120. Zhejiang Doer Biologics Corp Strategic initiatives
Table 121. Dicerna Pharmaceuticals Inc Profiles
Table 122. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Introduction
Table 123. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 124. Dicerna Pharmaceuticals Inc Strategic initiatives
Table 125. ChemomAb Ltd Profiles
Table 126. ChemomAb Ltd NASH Drug Pipeline Product Introduction
Table 127. ChemomAb Ltd NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 128. ChemomAb Ltd Strategic initiatives
Table 129. DURECT Corp Profiles
Table 130. DURECT Corp NASH Drug Pipeline Product Introduction
Table 131. DURECT Corp NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 132. DURECT Corp Strategic initiatives
Table 133. Eli Lilly and Co Profiles
Table 134. Eli Lilly and Co NASH Drug Pipeline Product Introduction
Table 135. Eli Lilly and Co NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 136. Eli Lilly and Co Strategic initiatives
Table 137. Enanta Pharmaceuticals Inc Profiles
Table 138. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Introduction
Table 139. Enanta Pharmaceuticals Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 140. Enanta Pharmaceuticals Inc Strategic initiatives
Table 141. EncuraGen Inc Profiles
Table 142. EncuraGen Inc NASH Drug Pipeline Product Introduction
Table 143. EncuraGen Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 144. EncuraGen Inc Strategic initiatives
Table 145. Engitix Ltd Profiles
Table 146. Engitix Ltd NASH Drug Pipeline Product Introduction
Table 147. Engitix Ltd NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 148. Engitix Ltd Strategic initiatives
Table 149. Heprotech Inc Profiles
Table 150. Heprotech Inc NASH Drug Pipeline Product Introduction
Table 151. Heprotech Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 152. Heprotech Inc Strategic initiatives
Table 153. Hinova Pharmaceuticals Inc Profiles
Table 154. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Introduction
Table 155. Hinova Pharmaceuticals Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 156. Hinova Pharmaceuticals Inc Strategic initiatives
Table 157. HK inno.N Corp Profiles
Table 158. HK inno.N Corp NASH Drug Pipeline Product Introduction
Table 159. HK inno.N Corp NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 160. HK inno.N Corp Strategic initiatives
Table 161. HotSpot Therapeutics Inc Profiles
Table 162. HotSpot Therapeutics Inc NASH Drug Pipeline Product Introduction
Table 163. HotSpot Therapeutics Inc NASH Drug Pipeline Production (Unit), Revenue (Million USD) (2018-2022)
Table 164. HotSpot Therapeutics Inc Strategic initiatives